Rx Marketplace Quarterly: Q2 2019 Pharmaceutical and Life Science

Start adding items to your reading lists:
or
Save this item to:
This item has been saved to your reading list.

In this issue of Rx Marketplace you will find an overview of recent market activity focusing on initial public offerings, venture funding and acquisitions. We also share our perspective on how to stay ahead of the ever changing drug pricing environment. 

We updated our SEC comment letter trends publication and not unexpectedly comments on revenue recognition continue to lead the chart. This was also a busy quarter for SEC rulemaking initiatives as we saw new proposals in several areas that will impact many pharmaceutical and life sciences companies. Finally, several cybersecurity incidents have recently affected our industry.

Updated SEC comment letter trends 

Our analysis of SEC comment letters identifies the frequency of topical areas addressed by the SEC staff and how their focus has evolved over time. We have updated the rankings and topics to include those comment letters issued through March 31, 2019. 

Spotlight on Cybersecurity 

Several major cybersecurity incidents have recently affected life sciences companies and their partners. PwC’s Health Research Institute (HRI) talked with two cybersecurity partners at PwC to better understand how companies can prepare for, respond to and investigate cybersecurity incidents and think about cybersecurity as a business enabler and competitive advantage.

Contact us

Laura Robinette

US Pharmaceutical & Life Sciences Assurance Leader, PwC US

Follow us